CN115151270A - iRhom2表位的蛋白结合剂 - Google Patents

iRhom2表位的蛋白结合剂 Download PDF

Info

Publication number
CN115151270A
CN115151270A CN202080082263.5A CN202080082263A CN115151270A CN 115151270 A CN115151270 A CN 115151270A CN 202080082263 A CN202080082263 A CN 202080082263A CN 115151270 A CN115151270 A CN 115151270A
Authority
CN
China
Prior art keywords
mef
dko
hir2
zxft
pmscv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080082263.5A
Other languages
English (en)
Chinese (zh)
Inventor
M·施奈德
K·泽勒
J·鲁厄
G·韦斯坎普
C·布洛贝尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York Relief And Disability Maintenance Special Surgery Hospital Association
Chirom Co ltd
Original Assignee
New York Relief And Disability Maintenance Special Surgery Hospital Association
Chirom Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York Relief And Disability Maintenance Special Surgery Hospital Association, Chirom Co ltd filed Critical New York Relief And Disability Maintenance Special Surgery Hospital Association
Publication of CN115151270A publication Critical patent/CN115151270A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202080082263.5A 2019-09-30 2020-09-30 iRhom2表位的蛋白结合剂 Pending CN115151270A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19200589 2019-09-30
EP19200589.0 2019-09-30
PCT/EP2020/077346 WO2021064009A1 (en) 2019-09-30 2020-09-30 Protein binders to irhom2 epitopes

Publications (1)

Publication Number Publication Date
CN115151270A true CN115151270A (zh) 2022-10-04

Family

ID=68104520

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080082263.5A Pending CN115151270A (zh) 2019-09-30 2020-09-30 iRhom2表位的蛋白结合剂

Country Status (7)

Country Link
US (1) US20240287172A1 (https=)
EP (1) EP4037699A1 (https=)
JP (2) JP2022550390A (https=)
CN (1) CN115151270A (https=)
AU (1) AU2020360849A1 (https=)
CA (1) CA3151450A1 (https=)
WO (1) WO2021064009A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024510415A (ja) 2021-03-01 2024-03-07 スキロム ゲゼルシャフト ミット ベシュレンクテル ハフツング ｉＲｈｏｍ２に対するヒト化抗体
US20240174744A1 (en) * 2021-03-29 2024-05-30 Scirhom Gmbh Methods of treatment using protein binders to irhom2 epitopes

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150241429A1 (en) * 2012-09-11 2015-08-27 Hospital For Special Surgery Irhom2 inhibition for the treatment of complement mediated disorders
CN106471130A (zh) * 2014-05-09 2017-03-01 杰克逊实验室 鉴定改变iRhom多肽活性的化合物的方法及其用途
CN109045056A (zh) * 2018-07-04 2018-12-21 重庆第二师范学院 多药载药靶向纳米颗粒及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
WO2003073843A2 (en) 2002-03-05 2003-09-12 Artemis Pharmaceuticals Gmbh Inbred embryonic stem-cell derived mice
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
KR20150056788A (ko) 2012-09-19 2015-05-27 애브비 바이오테라퓨틱스 인크. 면역원성이 감소된 항체의 동정 방법
US10024844B2 (en) * 2012-12-20 2018-07-17 Hospital For Special Surgery Identification of an inhibitor of iRhom1 or an inhibitor of iRhom2
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
CN113993534A (zh) * 2019-04-09 2022-01-28 特殊外科医院 针对iRhom2的蛋白结合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150241429A1 (en) * 2012-09-11 2015-08-27 Hospital For Special Surgery Irhom2 inhibition for the treatment of complement mediated disorders
CN106471130A (zh) * 2014-05-09 2017-03-01 杰克逊实验室 鉴定改变iRhom多肽活性的化合物的方法及其用途
CN109045056A (zh) * 2018-07-04 2018-12-21 重庆第二师范学院 多药载药靶向纳米颗粒及其制备方法和应用

Also Published As

Publication number Publication date
JP2025179064A (ja) 2025-12-09
US20240287172A1 (en) 2024-08-29
JP2022550390A (ja) 2022-12-01
AU2020360849A1 (en) 2022-04-14
EP4037699A1 (en) 2022-08-10
WO2021064009A1 (en) 2021-04-08
CA3151450A1 (en) 2021-04-08

Similar Documents

Publication Publication Date Title
JP7538721B2 (ja) 抗インターロイキン１７ａ抗体、医薬組成物、およびその使用
US7932055B2 (en) Soluble heterodimeric CD94/NKG2 receptors fusion proteins
TW201831516A (zh) 抗gpc3抗體
JP7022067B2 (ja) Ｆｏｘｐ３由来のペプチドに特異的なｔ細胞受容体様抗体
MX2014013590A (es) Anticuerpos monoclonales multiespecificos.
KR20170081699A (ko) Cd47 항체, 방법 및 용도
JP2025179064A (ja) ｉＲｈｏｍ２エピトープに結合するタンパク質バインダー
JP2019163254A (ja) レクチン様酸化ｌｄｌ受容体１抗体および使用法
CN109776678A (zh) 一种人源化pd-l1单克隆抗体、其制备方法和应用
CN113993534A (zh) 针对iRhom2的蛋白结合物
CN115043940B (zh) 抗人血清白蛋白抗体及其应用
US20240174744A1 (en) Methods of treatment using protein binders to irhom2 epitopes
JP2022514423A (ja) 生物学的結合分子の選別方法
US12404345B2 (en) Humanized antibodies against iRHOM2
JP4915919B2 (ja) インターフェロン産生細胞の活性調節剤
KR101972899B1 (ko) 소수성 테일 도메인이 제거된 먹장어 유래 VLRB 단백질과 C4bp 올리고머화 도메인이 연결된 융합 단백질 및 이의 용도
CN118613506A (zh) 一种抗原结合蛋白及其用途
JP2024534706A (ja) 二重特異性抗体及びその使用
CN117222669A (zh) 针对iRhom2的人源化抗体
JP7346576B2 (ja) 抗ｏｘ４０モノクローナル抗体とその応用
EA051567B1 (ru) Гуманизированные антитела против irhom2
CN119390838B (zh) 一种靶向ccr7的纳米抗体及其制备与应用
JP4059404B2 (ja) 甲状腺機能を刺激する活性を持つ抗体
CN101316930A (zh) T细胞粘附分子及其抗体
CN121736105A (zh) 抗ccr8抗体及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination